Praxis Precision logo

Praxis Precision

Stock
Stock
Ticker: PRAX
PRAX

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Praxis Precision is $6.75B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Praxis Precision's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$12.94. EPS indicates the company's profitability on a per-share basis.
Currently, 21 analysts cover Praxis Precision's stock, with a consensus target price of $650.00. Analyst ratings provide insights into the stock's expected performance.
Praxis Precision's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$378.05M. EBITDA measures the company's overall financial performance.
Praxis Precision has a free cash flow of -$305.55M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Praxis Precision employs approximately 168 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
The free float of Praxis Precision is 26.26M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$6.75B
EPS (TTM) 
-$12.94
Free Float 
26.26M
EBITDA (TTM) 
-$378.05M
Free Cashflow (TTM) 
-$305.55M

Pricing

52W span
$154.57$392.70

Analyst Ratings

The price target is $650.00 and the stock is covered by 21 analysts.

Buy

19

Hold

1

Sell

1

Information

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Employees
168
Industries
Major Pharmaceuticals
Sector
Health Care

Identifier

Primary Ticker
PRAX
Fundamentals & EOD data from FactSet
Join the conversation
Sign upLogin